Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Daavlin will exclusively manufacture the proprietary light device for use with SGX301 for the treatment of CTCL. Upon approval of SGX301 by the U.S FDA, Soligenix will promote SGX301 and the companion light device, and facilitate the direct purchase of the device from Daavlin.
Lead Product(s): Hypericin
Therapeutic Area: Oncology Product Name: SGX301
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Soligenix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 07, 2021